• Ulcerative Colitis Clinical Trial

    Now accepting participants for an ulcerative colitis clinical trial to study new investigational treatment QBECO SSI.

  • Crohn's disease clinical trial

    Restoring normal immune function to treat Crohn’s disease

  • Qu Biologics has begun a clinical trial in recurrent lung cancer


"The future of medicine lies in treatments that restore our body's innate capacity to heal."

~ Dr. Hal Gunn, CEO of Qu Biologics

Qu Biologics is at the forefront of a paradigm shift in the way we treat cancer and other immune-related disease. Rather than blocking or stimulating a single receptor or pathway, the company’s Site Specific Immunomodulators (SSIs) aim to restore the body’s normal immune response.

About Qu Biologics

Qu Biologics has discovered how our body’s immune response to acute infection helps our body clear cancer and other chronic inflammatory diseases. To learn more, read How SSIs Work. SSIs, which are derived from components of inactivated bacteria, are designed to activate the body’s innate immune response and restore normal immune function in the targeted organ or tissue to reverse the chronic inflammation underlying many chronic diseases including cancer, inflammatory bowel disease and other immune-related conditions. By restoring and empowering your own immune system, SSIs are designed to treat disease differently.

We bring excitement and passion to our work every day with the goal of creating treatments that will positively impact the lives of people living with chronic disease. Qu Biologics’ founder and CEO, Dr. Hal Gunn, is a clinician who for 20 years has worked to understand the link between our immune system and chronic disease, including cancer. Qu Biologics’ Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, leads Qu’s growing clinical trial program. Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology at the Geisel School of Medicine at Dartmouth College and recognized expert in immune cell trafficking to tumours, leads a growing team of Qu scientists investigating new promising applications of SSIs.

Currently, we are recruiting participants for a three Health Canada-approved clinical trials in Crohn’s disease, ulcerative colitis and recurrent lung cancer.

More information about the Crohn’s disease research trial and participation can be found at www.qucrohnstrial.com.

To learn more about the ulcerative colitis clinical trial, visit www.quibd.com or email ulcerativecolitis@quibd.com.

To learn more about the clinical trial in recurrent lung cancer, read Clinical Trials Lung Cancer or call the BC Cancer Agency Research Centre’s Lung Health Study line at 604-675-8088.


Upcoming Events

  1. JP Morgan Healthcare Conference

    January 11, 2016 - January 15, 2016
  2. Biotech Showcase 2016

    January 11, 2016 - January 13, 2016
  3. CDDW – Canadian Digestive Diseases Week 2016

    February 26, 2016 - February 29, 2016

Twitter Widget Plus

About SSIs Discovery

Our History

Qu Biologics was launched in 2007 by Dr. Hal Gunn and Rob Freeman.



Join a team of innovators who share a passion to make a difference.


How SSIs Work

SSIs are designed to restore your normal immune response.


Efficacy and Safety Studies

More than 270 patients have been treated with SSI therapy in a compassionate use program.